scispace - formally typeset
Search or ask a question
Institution

University of British Columbia

EducationVancouver, British Columbia, Canada
About: University of British Columbia is a education organization based out in Vancouver, British Columbia, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 89939 authors who have published 209679 publications receiving 9226862 citations. The organization is also known as: UBC & The University of British Columbia.


Papers
More filters
Journal ArticleDOI
29 Jan 2009-Nature
TL;DR: In this paper, the authors reported frequent mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%), and ocular melanoma of the uvea (46%).
Abstract: BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway. However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown. Here we report frequent somatic mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%). The mutations occur exclusively in codon 209 in the Ras-like domain and result in constitutive activation, turning GNAQ into a dominant acting oncogene. Our results demonstrate an alternative route to MAP kinase activation in melanocytic neoplasia, providing new opportunities for therapeutic intervention.

1,266 citations

Journal ArticleDOI
TL;DR: It is confirmed that illusory conjunctions are frequently experienced among unattended stimuli varying in color and shape, and that they occur also with size and solidity (outlined versus filled-in shapes).

1,262 citations

Journal ArticleDOI
TL;DR: In this paper, the authors propose a statisticalique du rapport de vraisemblance construite a partir de la distribution conditionnelle des observations, and donne les estimateurs du maximum de VRAISEMblance for les parametres de nuisance.
Abstract: On propose une statistique du rapport de vraisemblance construite a partir de la distribution conditionnelle des observations, etant donne les estimateurs du maximum de vraisemblance pour les parametres de nuisance

1,261 citations

Journal ArticleDOI
Peter A. R. Ade1, Nabila Aghanim2, Zeeshan Ahmed3, Randol W. Aikin4  +354 moreInstitutions (75)
TL;DR: Strong evidence for dust and no statistically significant evidence for tensor modes is found and various model variations and extensions are probe, including adding a synchrotron component in combination with lower frequency data, and find that these make little difference to the r constraint.
Abstract: We report the results of a joint analysis of data from BICEP2/Keck Array and Planck. BICEP2 and Keck Array have observed the same approximately 400 deg2 patch of sky centered on RA 0h, Dec. −57.5deg. The combined maps reach a depth of 57 nK deg in Stokes Q and U in a band centered at 150 GHz. Planck has observed the full sky in polarization at seven frequencies from 30 to 353 GHz, but much less deeply in any given region (1.2 μK deg in Q and U at 143 GHz). We detect 150×353 cross-correlation in B-modes at high significance. We fit the single- and cross-frequency power spectra at frequencies above 150 GHz to a lensed-ΛCDM model that includes dust and a possible contribution from inflationary gravitational waves (as parameterized by the tensor-to-scalar ratio r). We probe various model variations and extensions, including adding a synchrotron component in combination with lower frequency data, and find that these make little difference to the r constraint. Finally we present an alternative analysis which is similar to a map-based cleaning of the dust contribution, and show that this gives similar constraints. The final result is expressed as a likelihood curve for r, and yields an upper limit r0.05<0.12 at 95% confidence. Marginalizing over dust and r, lensing B-modes are detected at 7.0σ significance.

1,255 citations

Journal ArticleDOI
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Abstract: Purpose Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas. Patients and Methods In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin’s lymphoma (HL) after autologous stem-cell transplantation (auto-SCT). Patients had histologically documented CD30-positive HL by central pathology review. A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The primary end point was the overall objective response rate (ORR) determined by an independent radiology review facility. Results The ORR was 75% with complete remission (CR) in 34% of patients. The median progression-free survival time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months. After a median observation time of more than 1.5 years, 31 patients were alive and free of documented progressive disease. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. Conclusion The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy. J Clin Oncol 30:2183-2189. © 2012 by American Society of Clinical Oncology

1,254 citations


Authors

Showing all 90682 results

NameH-indexPapersCitations
Gordon H. Guyatt2311620228631
John C. Morris1831441168413
Douglas Scott1781111185229
John R. Yates1771036129029
Deborah J. Cook173907148928
Richard A. Gibbs172889249708
Evan E. Eichler170567150409
James F. Sallis169825144836
Michael Snyder169840130225
Jiawei Han1681233143427
Michael Kramer1671713127224
Bruce L. Miller1631153115975
Peter A. R. Ade1621387138051
Marc W. Kirschner162457102145
Kaj Blennow1601845116237
Network Information
Related Institutions (5)
University of Toronto
294.9K papers, 13.5M citations

99% related

University of Minnesota
257.9K papers, 11.9M citations

96% related

University of Washington
305.5K papers, 17.7M citations

96% related

University of California, San Diego
204.5K papers, 12.3M citations

96% related

Cornell University
235.5K papers, 12.2M citations

95% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20241
2023307
20221,209
202113,228
202012,052
201910,934